Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
narcolepsy
Biotech
Alkermes impresses in full-throttle narcolepsy race with Takeda
The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect despite being administered less frequently.
Nick Paul Taylor
Jun 4, 2024 9:01am
Phase 2b narcolepsy win powers Takeda toward pivotal trials
Feb 9, 2024 6:02am
Jazz halts sleep disorder med trial over 'visual disturbances'
Nov 29, 2023 10:50am
Takeda cuts ties to cancer drug landed in $120M Turnstone deal
Jul 28, 2022 7:00am
With narcolepsy approval a year out, antsy Avadel slashes staff
Jun 30, 2022 11:04am
Avadel's shares crumble as narcolepsy drug delayed yet again
May 26, 2022 10:53am